K. L. Nastiuk

This study shows that stromal compartments in a mouse model of BPH are resistant to castration-induced regression, suggesting the need for additional therapies.

This study shows TNF signaling is required for castration-induced vascular damage in prostate cancer, which contributes to tumor regression.

This study shows that glucocorticoid signaling delays castration-induced regression in murine prostate cancer models by maintaining tumor proliferation through GR activation, which can be blocked by the GR antagonist relacorilant.

Patient data and mouse models suggest that repurposing tumor necrosis factor alpha blockade reduces inflammation-mediated prostatic hyperplasia.